公司概述
Pomdoctor Limited operates primarily within the healthcare sector, specifically functioning as a pharmaceutical retailer that utilizes subsidiaries to provide an online B2C portal for selling pharmaceutical products. The company has also developed an online medical services platform dedicated to chronic disease management within the Chinese market, focusing on pharmaceutical services and chronic disease management. In terms of operational scale, Pomdoctor Limited maintains a market capitalization of $29.50M, generates an annual revenue of $366.86M, and employs 156 staff members. These financial figures indicate that while the company commands a substantial annual revenue base relative to its market capitalization, the valuation suggests a market perspective that diverges significantly from its revenue generation capabilities, positioning it as a small-cap entity with high revenue output.
财务健康
The company reported a revenue of $366.86M over the trailing twelve months, yet this revenue generated a net income of $-148,901,728 and an EBITDA of $-25,949,008, revealing a cost structure where operating expenses substantially exceed gross profits. This significant gap between revenue and net income highlights a severe challenge in covering fixed costs and operational overheads, resulting in a profit margin of -40.6%. The company also recorded a free cash flow of $-12,435,489, which indicates a lack of financial flexibility as the business is consuming cash rather than generating it for reinvestment or debt reduction. The gross margin stands at 14.1%, while the operating margin is -6.5%, collectively pointing to a business model under severe pressure to maintain profitability before reaching the bottom line. Furthermore, the company holds $5.75M in cash against a total debt load of $456.02M, creating a precarious balance sheet that is highly leveraged rather than conservative. The current ratio of 0.17 further confirms that the company's short-term liquid assets are insufficient to cover its short-term liabilities, signaling potential liquidity constraints. Additionally, the return on equity is listed as N/A due to negative equity, and the return on assets is -32.6%, metrics that reveal management has struggled to generate returns on the capital employed by shareholders or creditors.
估值评估
Pomdoctor Limited has a trailing P/E ratio of N/A and a forward P/E ratio of N/A, implying that the market currently cannot apply a traditional earnings-based valuation metric due to the absence of positive earnings. The price-to-book ratio is reported at -0.03, which indicates a market valuation that is mathematically inverted relative to the company's book value, reflecting the negative net income position. Alternative valuation metrics such as the price-to-sales ratio of 0.08 and an EV/EBITDA of -87.40 suggest that the stock is priced extremely low relative to its sales, though the negative EV/EBITDA underscores the fundamental lack of earnings power. The stock has traded between a 52-week high of $6.43 and a 52-week low of $0.19, and given the price-to-sales ratio of 0.08, the current price sits significantly below the 52-week high, reflecting a deep discount from recent peaks. The beta value is listed as N/A, meaning that specific volatility data relative to the broader market is not currently available for this ticker.
Growth & Income
The company demonstrated a revenue growth rate of 16.2% year-over-year, whereas the earnings growth rate is N/A due to the reported net loss, indicating that top-line expansion has not yet translated into bottom-line profitability. As a non-dividend payer, Pomdoctor Limited has a dividend yield of N/A and a payout ratio of 0.0%, meaning the company does not distribute earnings to shareholders but instead retains all capital, albeit negative in this instance, for operational use. The absence of a dividend payout ratio suggests that the company is not returning cash to investors, a common trait for growth-stage firms or those currently facing financial distress. Overall, the growth and income profile is characterized by robust revenue expansion that fails to cover the substantial losses incurred, resulting in a negative return on assets and no income distribution to equity holders.